snow leopard digital download for mac 
purchase publisher software 
download microsoft word 2011 for mac 
web premium cs6 download mac windows 7 price best buy cheap autocad 2012 cheapest windows 7 ultimate download microsoft access 2007 for mac download acrobat 9 reader viagra for australia viagra online melbourne australia viagra australia generic
prednisone tapering dose zithromax tablets dosage ventolin syrup for babies side effects
viagra professionnelle echte kamagra viagra indien bestellen
no prescription amoxicillin 
generic name for zithromax z pak 
order ciprofloxacin 500mg 
acheter baclofene flagyl 500 mg commander baclofene en ligne

Expand+Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer

Sun, Apr 4, 2010

Oral Cancer News

Source: Clin Cancer Res; 16(7); 2138–46
Authors: Anthony C. Nichols et al.

Purpose:
Oropharyngeal squamous cell carcinoma (OPSCC) associated with human papilloma virus (HPV) is rapidly growing in incidence. Despite better prognosis than OPSCC associated with traditional risk factors, treatment failure still occurs in a significant proportion of patients. We had identified the antiapoptotic protein Bcl2 as a marker for poor outcome in advanced OPSCC treated with concurrent chemoradiation. To determine whether Bcl2 and HPV together might further characterize treatment response, we examined whether the prognostic value of Bcl2 was independent of HPV status.

Experimental Design:
Pretreatment tumor biopsies from 68 OPSCC patients were tested for HPV by in situ hybridization and were immunostained for Bcl2 to evaluate relations with disease-free (DFS) and overall survival following platin-based concurrent chemoradiation. Median follow-up among surviving patients was 47 months (range, 10-131 months).

Results:
Bcl2 and HPV independently predicted DFS and overall survival. Hazard ratios (with 95% confidence interval) for positive versus negative status in bivariate Cox proportional hazard analysis of DFS were 6.1 (1.8-21) for Bcl2 and 0.11 (0.035-0.37) for HPV. Only 1 of 32 HPV-positive/Bcl2-negative tumors recurred. Pretreatment Bcl2 expression was specifically associated with distant metastasis; five of six distant metastases occurred in the <40% of patients whose primary tumors were Bcl2 positive.

Conclusions:
Independent of HPV status, pretreatment Bcl2 expression identifies a subset of OPSCC patients having increased risk of treatment failure, particularly through distant metastasis, after concurrent chemoradiation. Considering HPV and Bcl2 together should help in devising better personalized treatments for OPSCC.

Note: Supplementary data for this article are available at Clinical Cancer Research Online .

Authors:
Anthony C. Nichols1, Dianne M. Finkelstein2,3, William C. Faquin4, William H. Westra8, Edmund A. Mroz3,5, Peter Kneuertz1, Shahnaz Begum8, William A. Michaud3,5, Paul M. Busse6, John R. Clark7, and James W. Rocco1,3,5

Authors’ affiliations:
1 Department of Otolaryngology, Massachusetts Eye and Ear Infirmary; .
2 Biostatistics Center,
3 Cancer Center, and Departments of
4 Pathology,
5 Surgery,
6 Radiation Oncology, and
7 Medicine, Massachusetts General Hospital, Boston Massachusetts;
8 Department of Pathology, Johns Hopkins University, Baltimore Maryland

Print Friendly
Be Sociable, Share!
, , , , ,

Leave a Reply

You must be logged in to post a comment.